Evidence map›Paper›PMID 27897391›Full record

SynthesisJournal of cachexia, sarcopenia and muscle2017

A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project.

Mochamat, Henning Cuhls, Milka Marinova, Stein Kaasa, Christiane Stieber, Rupert Conrad, Lukas Radbruch, Martin Mücke

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Journal of cachexia, sarcopenia and muscle, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07231120 (A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia), which is not on this map. Cited by 56 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 7 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07231120 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia

TypeinterventionalSponsorJiangsu Nutai Biologics Co., LtdRan2025 to 2026Enrolled54ConditionsCachexia-Anorexia Syndrome, Solid Tumor MalignanciesArmsSXRN Injection
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 7 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Protein intake and muscle mass maintenance in patients with cancer types with high prevalence of sarcopenia: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Understanding cachexia and its impact on lung cancer and beyond.Chinese medical journal pulmonary and critical care medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

MochamatDepartment of Palliative Medicine, University Hospital of Bonn, Bonn, Germany.
Henning CuhlsDepartment of Palliative Medicine, University Hospital of Bonn, Bonn, Germany.
Milka MarinovaDepartment of Radiology, University Hospital of Bonn, Bonn, Germany.
Stein KaasaEuropean Palliative Care Research Centre, Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Christiane StieberDepartment of Human Genetics, University Hospital of Bonn, Bonn, Germany.
Rupert ConradDepartment of Psychosomatic Medicine and Psychotherapy, University Hospital of Bonn, Bonn, Germany.
Lukas RadbruchDepartment of Palliative Medicine, University Hospital of Bonn, Bonn, Germany.
Martin MückeDepartment of Palliative Medicine, University Hospital of Bonn, Bonn, Germany.
University Hospital Bonn · DEDr. Kariadi Hospital · IDMalteser-Krankenhaus · DENorwegian University of Science and Technology · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We provide a systematic review to support the European Palliative Care Research Collaboration development of clinical guidelines for cancer patients suffering from cachexia. CENTRAL, MEDLINE, PsycINFO, ClinicalTrials.gov, and a selection of cancer journals have been searched up until 15 April 2016. The systematic literature research yielded 4214 publications with 21 of these included in the final evaluation. Regarding minerals, our search identified only one study examining the use of magnesium with no effect on weight loss. As far as vitamins are concerned, vitamin E in combination with omega-3 fatty acids displayed an effect on survival in a single study, vitamin D showed improvement of muscle weakness in prostate cancer patients, and vitamin C supplementation led to an improvement of various quality of life aspects in a sample with a variety of cancer diagnoses. For proteins, a combination therapy of β-hydroxy-β-methylbutyrate (HMB), arginine, and glutamine showed an increase in lean body mass after 4 weeks in a study of advanced solid tumour patients, whereas the same combination did not show a benefit on lean body mass in a large sample of advanced lung and other cancer patients after 8 weeks. L-carnitine led to an increase of body mass index and an increase in overall survival in advanced pancreatic cancer patients. Adverse effects of food supplementation were rare and showed mild intensity. There is not enough solid evidence for the use of minerals, vitamins, proteins, or other supplements in cancer. No serious adverse effects have been reported with dietary supplementation.

Indexed as

Dietary SupplementsCachexiaHumansMineralsNeoplasmsPalliative CareProteinsVitaminsMineralsProteinsVitaminsCancer cachexiaDietary supplementsGuidelinesMicronutrientsMineralsSystematic reviewVitamins

Identifiers

PMID27897391
PMCPMC5326814
OpenAlexW2480421002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.